Table 3.
Plasma concentrations of IL-1β, IL-6, Hs-CRP, CIICP, and C2C from 0 to 12 weeks.
| 0 Week | 4 Week | 8 Week | 12 Week | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MSM Group | Placebo Group | Difference | p Value 1 | MSM Group | Placebo Group | Difference | p Value 1 | MSM Group | Placebo Group | Difference | p Value 1 | MSM Group | Placebo Group | Difference | p Value 1 | ||
| (Unit) | Mean ± SD | Mean ± SD | (95% CI) | Mean ± SD | Mean ± SD | (95% CI) | Mean ± SD | Mean ± SD | (95% CI) | Mean ± SD | Mean ± SD | (95% CI) | |||||
| IL-1β | (pg/mL) | 0.0 ± 0.1 | 0.0 ± 0.0 | 0.0 (0.0 to 0.1) |
0.478 | 0.0 ± 0.1 | 0.0 ± 0.0 | 0.0 (0.0 to 0.0) |
0.324 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 (0.0 to 0.0) |
0.761 | 0.0 ± 0.1 | 0.0 ± 0.0 | 0.0 (0.0 to 0.1) |
0.349 |
| IL-6 | (pg/mL) | 1.0 ± 0.8 | 1.0 ± 0.6 | 0.0 (−0.3 to 0.3) |
0.937 | 1.4 ± 1.0 | 1.4 ± 1.0 | 0.1 (−0.4 to 0.5) |
0.807 | 1.2 ± 0.6 | 1.4 ± 0.7 | -0.2 (−0.5 to 0.1) |
0.227 | 1.2 ± 0.6 | 1.3 ± 0.8 | −0.1 (−0.4 to 0.3) |
0.737 |
| Hs-CRP | (mg/dL) | 0.2 ± 0.3 | 0.1 ± 0.2 | 0.0 (−0.1 to 0.1) |
0.428 | 0.2 ± 0.3 | 0.2 ± 0.5 | 0.0 (−0.2 to 0.2) |
0.856 | 0.1 ± 0.2 | 0.1 ± 0.2 | 0.0 (−0.1 to 0.1) |
0.854 | 0.2 ± 0.4 | 0.1 ± 0.2 | 0.1 (−0.1 to 0.2) |
0.306 |
| PⅡCP | (ng/mL) | 111.6 ± 58.6 | 94.9 ± 45.5 | 16.7 (−6.8 to 40.2) |
0.160 | 121.9 ± 45.2 | 112.1 ± 33.7 | 9.7 (−8.1 to 27.6) |
0.280 | 135.2 ± 76.9 | 106.2 ± 70.6 | 29.0 (−3.9 to 61.9) |
0.083 | 61.4 ± 18.6 | 60.0 ± 22.8 | 1.5 (−7.8 to 10.7) |
0.754 |
| CⅡC | (ng/mL) | 154.8 ± 30.0 | 146.3 ± 21.7 | 8.5 (−3.2 to 20.3) |
0.152 | 164.6 ± 24.6 | 167.3 ± 31.6 | −2.7 (−15.3 to 9.8) |
0.667 | 129.0 ± 17.1 | 124.8 ± 16.2 | 4.1 (−3.3 to 11.6) |
0.270 | 144.9 ± 22.8 | 141.3± 25.3 | 3.6 (−7.1 to 14.3) |
0.508 |
CI, confidence interval; 1 Welch’s t-test assessed differences between the MSM and placebo groups for 0, 4, 8, and 12 weeks.